New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 11, 2014
04:55 EDTULTI, ULTI, ULTI, CVM, CVM, CVM, ELLI, ELLI, ELLI, ISIL, ISIL, ISIL, MOVE, MOVE, MOVE, VECO, VECO, VECO, IGTE, IGTE, IGTE, OLED, OLED, OLED, ISSI, ISSI, ISSI, OSIS, OSIS, OSIS, NICE, NICE, NICE, NCR, NCR, NCR, SCOR, SCOR, SCOR, AUDC, AUDC, AUDC, INAP, INAP, INAPOppenheimer to hold a conference
17th Annual Technology, Internet & Communications Conference to be held in Boston on August 12-13.
News For ULTI;AUDC;SCOR;NCR;NICE;OSIS;ISSI;OLED;IGTE;VECO;MOVE;ISIL;ELLI;CVM;INAP From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
May 13, 2015
17:51 EDTISSIIntegrated Silicon up 6% following buyout proposal from Cypress Semiconductor
Subscribe for More Information
17:16 EDTISSICypress Semiconductor proposes to buy Integrated Silicon for $19.75 per share
Subscribe for More Information
17:12 EDTISSICypress Semiconductor proposes to buy Integrated Silicon for $19.75 per share
Subscribe for More Information
09:36 EDTVECOVeeco management to meet with Needham
Subscribe for More Information
09:00 EDTCVMCEL-SCI receives authorization to conduct Phase 3 Multikine trial in Italy
CEL-SCI Corporation announced that the Italian Medicines Agency has authorized the company to commence patient enrollment for its ongoing Phase 3 trial of its investigational immunotherapy Multikine in patients with advanced primary squamous cell carcinoma of the oral cavity/soft palate, a type of head and neck cancer. Italy is the 23rd country to authorize CEL-SCIís Phase 3 trial for patient enrollment. Having surpassed its originally planned milestone of receiving authorization to conduct the Phase 3 study from 21 countries, CEL-SCI is now aiming to expand the trial into a total of approximately 100 clinical centers in about 25 countries. As of April 30, 2015, 437 patients had been enrolled in the global Phase 3 study. The Multikine Phase 3 study is enrolling patients with advanced primary squamous cell carcinoma of the head and neck. The objective of the study is to demonstrate a statistically significant improvement in the overall survival of enrolled patients who are treated with the Multikine treatment regimen plus standard of care vs. subjects who are treated with SOC only.
08:18 EDTSCORcomScore reinstated with a Buy at Goldman
Subscribe for More Information
08:02 EDTNCRNCR Corp.'s SelfServ Self-Checkout selected by Magnit
Subscribe for More Information
07:10 EDTISILB. Riley to hold a conference
Subscribe for More Information
07:08 EDTOSISOppenheimer to hold a conference
Subscribe for More Information
May 12, 2015
11:40 EDTNICENICE Systems moves up on a positive mention by Navellier
Subscribe for More Information
10:01 EDTVECOOn The Fly: Analyst Initiation Summary
Subscribe for More Information
08:20 EDTNCRNCR Corp. software selected by Early Warning
Subscribe for More Information
08:07 EDTSCORSunTrust to hold a conference
Subscribe for More Information
07:51 EDTISILDeutsche Bank to hold a conference
Subscribe for More Information
07:05 EDTVECOVeeco initiated with a Buy at Benchmark Co.
Subscribe for More Information
06:44 EDTOSISOSI Systems management to meet with Benchmark
Meeting to be held in New York on May 12 hosted by Benchmark.
05:45 EDTNICENICE Systems price target raised to $74 from $65 at Imperial Capital
Imperial Capital raised its price target for NICE Systems to $74 after the company upped its guidance for 2015. The firm keeps an Outperform rating on the name.
May 11, 2015
10:44 EDTNICEClal Insurance reports 5.2% passive stake in NICE Systems
Subscribe for More Information
10:33 EDTISILIntersil management to meet with Piper Jaffray
Subscribe for More Information
08:05 EDTCVMCEL-SCI receives authorization to conduct Phase 3 Multikine trial in Spain
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use